227 results on '"Herbert, Andrew S."'
Search Results
2. Two point mutations in protocadherin-1 disrupt hantavirus recognition and afford protection against lethal infection
3. Seroprevalence as an Indicator of Undercounting of COVID-19 Cases in a Large Well-Described Cohort
4. Antibodies targeting Crimean-Congo hemorrhagic fever virus GP38 limit vascular leak and viral spread
5. Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies
6. Crimean-Congo Hemorrhagic Fever Survivors Elicit Protective Non-Neutralizing Antibodies that Target 11 Overlapping Regions on Viral Glycoprotein GP38
7. SARS-CoV-2 Aerosol and Intranasal Exposure Models in Ferrets
8. Development of an antibody cocktail for treatment of Sudan virus infection
9. Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors
10. Structural basis of broad ebolavirus neutralization by a human survivor antibody
11. Protocadherin-1 is essential for cell entry by New World hantaviruses
12. A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses
13. Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19
14. 1143. Prophylactic and Therapeutic Activity of AZD7442 (Tixagevimab/Cilgavimab) in SARS-CoV-2 Hamster Challenge Models
15. Novel Small Molecule Entry Inhibitors of Ebola Virus
16. Two point mutations in protocadherin-1 disrupt Andes hantavirus recognition and afford protection against lethal infection
17. Lassa virus entry requires a trigger-induced receptor switch
18. Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses
19. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
20. Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-Naïve and Experienced Individuals
21. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease
22. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays
23. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants
24. Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity
25. AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans
26. Characterization of an Anti-Ebola Virus Hyperimmune Globulin Derived From Convalescent Plasma
27. Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy
28. A combination of RBD and NTD neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants
29. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes
30. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever
31. Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets
32. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
33. Ebola virus entry requires the cholesterol transporter Niemann–Pick C1
34. VIRUS ENTRY: Lassa virus entry requires a trigger-induced receptor switch
35. Characterization of an Anti-Ebola Virus Hyperimmune Globulin Derived From Convalescent Plasma.
36. An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19
37. Broad neutralization of SARS-related viruses by human monoclonal antibodies
38. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening and in vitro assays
39. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2
40. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition
41. Broad neutralization of SARS-related viruses by human monoclonal antibodies
42. Neutralizing Antibodies against Crimean–Congo Hemorrhagic Fever Virus Derived from a Human Survivor
43. Animal Model Prescreening: Pre-exposure to SARS-CoV-2 impacts responses in the NHP model
44. Mapping the Interface between New World Hantaviruses and Their Receptor, PCDH1
45. Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein
46. A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates
47. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection
48. Human antibody cocktail deploys multiple functions to confer pan-ebolavirus protection
49. Two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates
50. Structural Basis of Broad Ebolavirus Neutralization by a Human Survivor Antibody
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.